EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 16th, 2014 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • California
NOW THEREFORE in consideration of the covenants in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged by the parties, the parties agree as follows:
LORUS THERAPEUTICS INC. EXECUTIVE EMPLOYMENT AGREEMENT for AVANISH VELLANKIExecutive Employment Agreement • May 16th, 2014 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (the “Agreement”), made between Lorus Therapeutics Inc. (the “Company”) and Avanish Vellanki (“Executive”) (together, the “Parties”), is effective as of November 29th, 2013 (the “Effective Date”). From and following the Effective Date, this Agreement shall replace and supersede that certain Consulting Services Agreement between Executive and the Company entered into as of November 4, 2013 (the “Consulting Agreement”); provided that, Executive will retain the right to receive all consulting fees earned as of the Effective Date, pursuant to the terms of the Consulting Agreement.
UNDERWRITING AGREEMENTUnderwriting Agreement • May 16th, 2014 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
RBC Dominion Securities Inc. (the “Lead Underwriter”), Roth Capital Partners, LLC (“ROTH”) and Cormark Securities Inc. (collectively with the Lead Underwriter, the “Underwriters”) understand that Lorus Therapeutics Inc. (the “Company”):
LORUS THERAPEUTICS INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 16th, 2014 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
NOW THEREFORE in consideration of the covenants in this Agreement and for other good and valuable consideration, including, without limitation, the grant of stock options described herein, the receipt and sufficiency of which are acknowledged by the parties, the parties agree as follows:
UNDERWRITING AGREEMENTUnderwriting Agreement • May 16th, 2014 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
The undersigned, Clarus Securities Inc. (“Clarus”) and Canaccord Genuity Corp. (“Canaccord”, and Clarus and Canaccord together, the “Co-Lead Underwriters”), Jennings Capital Inc. and D & D Securities Inc. (collectively with the Co-Lead Underwriters, the “Underwriters” and each individually an “Underwriter”), understand that Lorus Therapeutics Inc. (“Lorus” or the “Corporation”) proposes to issue and sell 12,730,000 common shares of the Corporation (the “Purchased Securities”) at a price of $0.55 per share (the “Purchase Price”). The offering of the Purchased Securities is hereby referred to as the “Offering”.
